United States Shingles Vaccines Market to Grow at 10.0% CAGR | Recombinant Vaccines Lead with 60% Share Driven by Rising Elderly Immunization Rates

Leander, Texas and TOKYO, Japan - Dec.10.2025
Market Size
As per DataM Intelligence research report, "The Global Shingles Vaccines Market is estimated to grow at a CAGR of 10.00% during the forecast period 2024-2031." Increasing awareness about shingles prevention and rising vaccination rates among the elderly population are driving market growth.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/shingles-vaccines-market?praveen

United States: Recent Industry Developments
✅ In November 2025, major U.S. vaccine manufacturers expanded production of recombinant shingles vaccines to meet rising demand among adults aged 50+. The enhancement supports nationwide immunization programs and strengthens U.S. leadership in preventive healthcare.

✅ In October 2025, the CDC collaborated with pharmaceutical companies to improve distribution of shingles vaccines across pharmacies and healthcare centers, ensuring better accessibility in rural and urban regions. This boosts national vaccination coverage.

✅ In September 2025, U.S. biotechnology firms advanced R&D for next-generation shingles vaccines with longer-lasting immunity and fewer doses, aiming to improve patient compliance. This elevates innovation in the U.S. vaccine landscape.

Japan: Recent Industry Developments
✅ In November 2025, Japanese pharmaceutical companies introduced improved recombinant shingles vaccines tailored for elderly populations, offering stronger protection and reduced side effects. This reinforces Japan's focus on aging-related healthcare solutions.

✅ In October 2025, Japan's Ministry of Health expanded reimbursement programs for shingles vaccination, increasing affordability and improving national immunization rates. This strengthens adoption across the country.

✅ In September 2025, Japanese vaccine developers collaborated on advanced adjuvant technologies to boost immune response in shingles vaccines, supporting long-term protection. This enhances Japan's vaccine innovation capabilities.

Global: Recent Industry Developments
✅ In 2025, global demand for shingles vaccines increased significantly due to rising awareness of shingles complications and strong vaccination recommendations across North America, Europe, and Asia-Pacific.

✅ In 2025, major vaccine manufacturers worldwide expanded capacity for recombinant and adjuvanted shingles vaccines, ensuring stable supply amid growing immunization campaigns.

✅ In 2024-2025, clinical trials advanced for next-generation shingles vaccines aimed at providing longer durability, broader age eligibility, and improved safety profiles, supporting global innovation.

✅ In 2025, international collaborations between governments, pharmaceutical companies, and healthcare organizations strengthened global distribution networks, improving access to shingles vaccines in emerging markets.

Shingles Vaccines Market Key Drivers :
- The shingles vaccines market is expanding as aging populations, healthcare providers, and public health agencies increasingly prioritize vaccination to prevent herpes zoster and its complications, including postherpetic neuralgia. Shingles vaccines provide long-term immunity by boosting varicella-zoster virus protection, with high-efficacy recombinant vaccines driving broader adoption. Rising awareness of adult immunization, growing burden of shingles among older adults, and expanding immunization programs are driving market growth. Advancements in recombinant vaccine technologies, improved adjuvant systems, and long-duration immunity research are further enhancing vaccine effectiveness and safety.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/shingles-vaccines-market?praveen

Major Key Players
GlaxoSmithKline plc., Merck & Co. Inc., SK Bioscience, GC Pharma, Vaccitech, Geneone Life Science, Shulov Innovative Science, and EYEGENE lnc.,

Key Segments:
- By Product
Recombinant shingles vaccines lead with 60% share, driven by their higher efficacy, strong immune response, and increasing recommendations for adult immunization. Live attenuated vaccines hold 30%, supported by long-standing availability and use in older adult populations. Other product types capture 10%, including pipeline formulations and combination vaccines under clinical evaluation.

- By Vaccine Type
Two-dose vaccines dominate with 65% share, fueled by superior protection, durability of response, and widespread adoption in national immunization programs. Single-dose vaccines account for 35%, preferred for convenience, lower cost, and suitability for populations with limited healthcare access.

- By Distribution Channel
Hospital pharmacies lead with 40% share, driven by physician-administered vaccination and higher patient trust in hospital-based immunization services. Retail pharmacies hold 35%, supported by ease of access, growing walk-in vaccination services, and expanding pharmacy immunizer programs. Other channels account for 25%, including clinics, government health centers, and online pharmacy platforms facilitating adult vaccination.

Regional Analysis - Shingles Vaccines Market
- North America - 40% Share
North America leads with 40%, driven by high vaccination awareness, strong healthcare infrastructure, and widespread adoption of adult immunization programs.

- Europe - 30% Share
Europe holds 30%, supported by rising elderly population, strong government vaccination initiatives, and increased uptake of recombinant shingles vaccines in Germany, UK, and France.

- Asia-Pacific - 20% Share
Asia-Pacific accounts for 20%, fueled by growing awareness of shingles prevention, expanding healthcare access, and rising aging populations in Japan, China, and South Korea.

- South America - 6% Share
South America holds 6%, driven by improving immunization coverage and growing demand for adult vaccines in Brazil and Argentina.

- Middle East & Africa - 4% Share
Middle East & Africa account for 4%, supported by gradual improvements in healthcare infrastructure and increasing adoption of preventive vaccines.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=shingles-vaccines-market?praveen
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?praveen

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.